Malignant pleural mesothelioma
Pemetrexed Disodium in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer
Pemetrexed Disodium in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Pemetrexed Disodium is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
Pemetrexed Disodium is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Malignant pleural mesothelioma
Pemetrexed Disodium in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer
Pemetrexed Disodium in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Pemetrexed Disodium is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
Pemetrexed Disodium is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Registration
Generic Drug
MenQuadfi
Meningococcal (Serogroup A) Polysaccharide 10 ug, Meningococcal (Serogroup C) Polysaccharide 10 ug, Meningococcal (Serogroup Y) Polysaccharide 10 ug, Meningococcal (Serogroup W135) Polysaccharide 10 ug
Meningococcal (Serogroup A) Polysaccharide 10 ug, Meningococcal (Serogroup C) Polysaccharide 10 ug, Meningococcal (Serogroup Y) Polysaccharide 10 ug, Meningococcal (Serogroup W135) Polysaccharide 10 ug
الاستخدامات الطبية المعتمدة
MenQuadfi is indicated for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
Ticagrelor co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with
- acute coronary syndromes (ACS) or
- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory
multiple myeloma who have received to three lines of therapy in combination with:
- Lenalidomide and dexamethasone; or
- Dexamethasone; or
- Daratumumab and dexamethasone; or
- Daratumumab and hyaluronidase-fihj and dexamethasone; or
- Isatuximab and dexamethasone.
Carfilzomib BOS is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received or more lines of therapy.
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory
multiple myeloma who have received to three lines of therapy in combination with:
- Lenalidomide and dexamethasone; or
- Dexamethasone; or
- Daratumumab and dexamethasone; or
- Daratumumab and hyaluronidase-fihj and dexamethasone; or
- Isatuximab and dexamethasone.
Carfilzomib is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received or more lines of therapy.
Adults Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Paediatric population Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary
haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease
Itraconazole Oral Solution is indicated:
- for the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.
- as prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e. < 500 cells/μL). At present, there are insufficient clinical efficacy data in the prevention of aspergillosis.
Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.
